Compare Definium Therapeutics Inc. Common Shares (DFTX) vs Nuvation Bio Inc. Class A Common Stock (NUVB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Definium Therapeutics Inc. Common Shares vs Nuvation Bio Inc. Class A Common Stock — how do they compare? Definium Therapeutics Inc. Common Shares trades at $34.01 (market cap $4.71B), while Nuvation Bio Inc. Class A Common Stock trades at $4.95 (market cap $1.71B). The key difference: Definium Therapeutics Inc. Common Shares is far larger — about 2.8× Nuvation Bio Inc. Class A Common Stock's market cap, and Definium Therapeutics Inc. Common Shares is trading nearer its 52-week high, Nuvation Bio Inc. Class A Common Stock nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Definium Therapeutics Inc. Common Shares for 0 Days and Nuvation Bio Inc. Class A Common Stock for 0 Days on average.
| DFTX | NUVB | |
|---|---|---|
Market Cap | $4.71B | $1.71B |
Volume | 1,966,636 | 5,448,712 |
Sector | Health | Health |
52-Week High | $48.45 | $9.54 |
52-Week Low | $10.68 | $3.41 |
Typical Hold Time | 0 Days | 0 Days |
Enterprise Value | $3.67B | $1.30B |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Definium Therapeutics Inc. Common Shares
Definium Therapeutics develops investigational treatments for psychiatric and neurological disorders. Formerly MindMed, it focuses on clinical-stage therapies based on novel psychoactive compounds.
Read more on DFTX →About Nuvation Bio Inc. Class A Common Stock
Nuvation Bio Inc. is a biopharmaceutical company focused on oncology, developing novel cancer treatments including taletrectinib (marketed as IBTROZI), a ROS1 inhibitor, and safusidenib, a brain-penetrant IDH1 inhibitor.
Read more on NUVB →
